title: The comparative clinical and economic benefits of drugs should be established and discussed as part of any formulary decision process.
authors.forename: Mary S
authors.initials: MS
authors.lastname: Richardson
authors.forename: Brian W
authors.initials: BW
authors.lastname: Bowers
authors.forename: Jonathan L
authors.initials: JL
authors.lastname: Petrie
mesh_terms: D000293:Adolescent; D000328:Adult; D002637:Chest Pain / Q000139:chemically induced*; D002648:Child; D003362:Cost-Benefit Analysis; D005260:Female; D005569:Formularies as Topic; D006801:Humans; D008881:Migraine Disorders / Q000188:drug therapy*; D017366:Serotonin Receptor Agonists / Q000009:adverse effects / Q000627:therapeutic use*; D018170:Sumatriptan / Q000009:adverse effects / Q000627:therapeutic use*; D014481:United States
chemical_list: D017366:Serotonin Receptor Agonists; D018170:Sumatriptan